Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2790)	11/10/2019 1:24:55 PM
From: DewDiligence_on_SI	Read Replies (2) \| Respond to of 3557

Inasmuch as BIIB is paying Samsung $100M in up-front cash, BIIB must be pretty confident that Samsung can handle the manufacturing part of the Eylea-biosimilar program. (Lucentis is easy to manufacture, so discussion needed about that program.) In my experience, biotech executives of companies whose drugs are being copied tend to overstate the manufacturing impediments. For instance, AGN and ABBV have said that making a Botox biosimilar is "nearly impossible," which is total BS, IMO. (RVNC is working on one.)